Words of wisdom. Re: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Morris MJ, Huang D, Kelly WK, et al. Eur Urol 2009;56:237-44.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 20845543.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Laboratory studies suggest that castration-resistant prostate cancer (CRPC) cell growth is suppressed by supraphysiologic doses of testosterone (T). In this study, 12 men received high doses of T transdermally for 7 d, for 4 mo, or until progression.The approach was safe and toxicity was mild, but responses were modest. Because serum T did not reach intended supraphysiologic levels, the authors urged more clinical testing.